Pediatric hearing loss

Christopher R Grindle1

  • 1Division of Otolaryngology, University of Connecticut School of Medicine, and Division of Otolaryngology-Head and Neck Surgery, Connecticut Children's Medical Center, Hartford, CT.

Pediatrics in Review
|November 2, 2014
PubMed

Insights

Universal newborn screening is recommended before 1 month, with follow-up testing by 3 months and intervention by 6 months for infants. Early hearing tests and tympanostomy tubes for persistent middle ear issues are crucial for children.

Area of Science:

  • Pediatrics
  • Audiology
  • Genetics

Background:

  • Congenital hearing loss is a common birth defect.
  • Genetic factors are the most frequent cause of congenital hearing loss, often nonsyndromic.
  • Early detection and intervention are critical for developmental outcomes.

Purpose of the Study:

  • To outline evidence-based guidelines for newborn hearing screening.
  • To provide recommendations for managing persistent middle ear effusion and hearing loss in children.
  • To emphasize the genetic basis of congenital hearing loss.

Main Methods:

  • Review of strong research findings.
  • Consideration of consensus statements in pediatric audiology and genetics.
  • Analysis of data on screening timelines and intervention timing.

Main Results:

  • Universal newborn screening recommended before 1 month, with repeat testing by 3 months and intervention by 6 months.
  • Tympanostomy tubes suggested for persistent middle ear effusion (≥3 months) with conductive hearing loss.
  • Age-appropriate hearing tests are advised for all children with suspected hearing loss.
  • Genetic factors are the primary cause of congenital hearing loss, predominantly nonsyndromic.

Conclusions:

  • Timely newborn screening and intervention significantly impact outcomes for congenital hearing loss.
  • Management of persistent middle ear effusion requires prompt audiological assessment and consideration of tympanostomy tubes.
  • Understanding the genetic etiology of hearing loss is essential for comprehensive care.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
395
Hearing01:31

Hearing

When we hear a sound, our nervous system is detecting sound waves—pressure waves of mechanical energy traveling through a medium. The frequency of the wave is perceived as pitch, while the amplitude is perceived as loudness.
47.7K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
972
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
532
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
918
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
391